Context Therapeutics Past Earnings Performance
Past criteria checks 0/6
Context Therapeutics's earnings have been declining at an average annual rate of -39.5%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Key information
-39.5%
Earnings growth rate
55.6%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | n/a |
Return on equity | -18.4% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Context Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -19 | 7 | 13 |
31 Mar 24 | 0 | -21 | 7 | 15 |
31 Dec 23 | 0 | -24 | 7 | 18 |
30 Sep 23 | 0 | -21 | 7 | 15 |
30 Jun 23 | 0 | -19 | 8 | 12 |
31 Mar 23 | 0 | -18 | 8 | 10 |
31 Dec 22 | 0 | -15 | 8 | 7 |
30 Sep 22 | 0 | -14 | 8 | 6 |
30 Jun 22 | 0 | -12 | 7 | 5 |
31 Mar 22 | 0 | -13 | 5 | 5 |
31 Dec 21 | 0 | -10 | 4 | 4 |
30 Sep 21 | 0 | -8 | 2 | 3 |
30 Jun 21 | 0 | -7 | 1 | 3 |
31 Mar 21 | 0 | -1 | 1 | 2 |
31 Dec 20 | 0 | 1 | 1 | 2 |
Quality Earnings: 6K9 is currently unprofitable.
Growing Profit Margin: 6K9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6K9 is unprofitable, and losses have increased over the past 5 years at a rate of 39.5% per year.
Accelerating Growth: Unable to compare 6K9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6K9 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 6K9 has a negative Return on Equity (-18.36%), as it is currently unprofitable.